AcquisitionsApr 6, 2026, 12:08 PM
Neurocrine Biosciences to Acquire Soleno Therapeutics for $53 per Share in Cash
AI Summary
Soleno Therapeutics entered into a definitive merger agreement with Neurocrine Biosciences, where Neurocrine will acquire all outstanding shares of Soleno for $53 per share in cash through a tender offer. The acquisition provides Neurocrine with Soleno's assets and pipeline, while Soleno's shareholders receive a cash premium for their shares.
Key Highlights
- Neurocrine Biosciences will commence a tender offer to purchase all outstanding shares of Soleno Therapeutics at $53 per share in cash.
- The offer is subject to customary closing conditions, including the tender of a majority of Soleno's outstanding shares and regulatory approvals.
- Following the successful completion of the tender offer, Neurocrine will complete a merger to acquire the remaining shares of Soleno.